Kidney gene panel
Renasight is a test to determine if there is a genetic cause for an individual’s kidney disease or if there is an increased hereditary risk due to family history. The test uses a blood or saliva sample to test 385 genes associated with chronic kidney disease (CKD). Results are available in approximately 3 weeks.
See more. Know more. With Renasight.
- Leverages next-generation sequencing and other methodologies on more than 380 genes associated with kidney disease
- Identifies autosomal dominant, autosomal recessive, and X-linked disorders
- Reports out pathogenic and likely pathogenic variants that were selected by genetic experts to provide actionable information
- > 99% detection rates across the genes screened1
Built on evidence
A recent New England Journal of Medicine publication assessing the incidence of genetic disease in kidney disease population found ~1 in 10 patients have a genetic diagnosis.2
Pinpoint and plan
Testing at the molecular level offers deeper insights to help deliver individualized patient care. In 89% of patients with kidney disease, a genetic diagnosis had implications for clinical management.2
Integrate Renasight for better patient care
Gain prognostic insight
Identify an etiology for patients with unknown cause of their kidney disease
Prescribe targeted therapies
Refer patients for extra-renal features
Test family members and offer genetic counseling
Enroll patients in clinical trials
Learn more about Renasight: Clinician brochure
Commitment to affordability
We welcome all insurance plans and provide affordable testing through a variety of payment methods. Natera offers discounted self-pay pricing and financial assistance through our compassionate care program.
The Natera team is here to help you with any billing or reimbursement questions at +1 650.425.4005.
Request more information about Renasight
1Natera data on file
2Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.